Home > Research > Publications & Outputs > Anti-IL5 therapies for chronic obstructive pulm...

Research

Associated organisational unit

Electronic data

  • Donovan_et_al-2019-Cochrane_Database_of_Systematic_Reviews

    Rights statement: This is the peer reviewed version of the following article:Donovan T, Crossingham I, Milan SJ, Wang R, Bradley P. Anti‐IL5 therapies for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2019, Issue 9. Art. No.: CD013432. DOI: 10.1002/14651858.CD013432 which has been published in final form at https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013432/full This article may be used for non-commercial purposes in accordance With Wiley Terms and Conditions for self-archiving.

    Final published version, 177 KB, PDF document

    Available under license: CC BY-NC: Creative Commons Attribution-NonCommercial 4.0 International License

Links

Text available via DOI:

View graph of relations

Anti-IL5 therapies for chronic obstructive pulmonary disease

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Published
Close
More...
<mark>Journal publication date</mark>20/09/2019
<mark>Journal</mark>Cochrane Database of Systematic Reviews
Issue number9
Volume2019
Number of pages11
Publication StatusPublished
<mark>Original language</mark>English

Abstract

This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:

To assess the efficacy and safety of monoclonal antibody therapies targeting IL‐5 signalling (anti‐IL‐5 or anti‐IL‐5Rα) compared with placebo in the treatment of adults with COPD.

Bibliographic note

This is the peer reviewed version of the following article:Donovan T, Crossingham I, Milan SJ, Wang R, Bradley P. Anti‐IL5 therapies for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2019, Issue 9. Art. No.: CD013432. DOI: 10.1002/14651858.CD013432 which has been published in final form at https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013432/full This article may be used for non-commercial purposes in accordance With Wiley Terms and Conditions for self-archiving.